Inventiva (IVA) Interest Expenses (2019 - 2025)
Inventiva (IVA) posted quarterly Interest Expenses of -$33958.8 for Q2 2025, down 26.14% year-over-year from -$45975.3 in Q2 2024, and down 27.12% quarter-over-quarter from -$26714.9 in Q4 2024.
Inventiva (IVA) Interest Expenses (2019 - 2025) Analysis & Trends
Inventiva's Interest Expenses history runs 7 years deep, the most recent figure standing at -$33958.8 for Q2 2025.
- In Q2 2025, Interest Expenses fell 26.14% year-over-year to -$33958.8; the TTM figure through Dec 2025 stood at $111439.1 (up 517.14% YoY), while the FY2025 annual figure was $252.5 million, up 165.75% from the prior year.
- Interest Expenses for Q2 2025 stood at -$33958.8, down from -$26714.9 in the prior quarter.
- The five-year high for Interest Expenses was $93805.6 in Q4 2021, with the low at -$2.7 million in Q1 2021.
- The 5-year median for Interest Expenses is -$26818.5 (2024), against an average of -$530827.1.
- Peak annual rise in Interest Expenses reached 337.09% in 2021, while the deepest fall reached 18794.71% in 2021.
- Inventiva's Interest Expenses stood at $93805.6 in 2021, then plunged by 41.27% to $55093.4 in 2022, then slumped by 189.84% to -$49493.2 in 2023, then jumped by 46.02% to -$26714.9 in 2024, then retreated by 27.12% to -$33958.8 in 2025.
- Business Quant data shows IVA's Interest Expenses at -$33958.8 in Q2 2025, -$26714.9 in Q4 2024, and -$26922.2 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Inventiva | 888.89 Mn | 888.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -33,958.79 |
| Jun 30, 2025 | -33,958.79 |
| Dec 31, 2024 | -26,714.89 |
| Dec 31, 2024 | -26,714.89 |
| Jun 30, 2024 | -26,922.19 |
| Jun 30, 2024 | -26,922.19 |
| Dec 31, 2023 | -49,493.24 |
| Dec 31, 2023 | -49,493.24 |
| Jun 30, 2023 | -25,045.26 |
| Jun 30, 2023 | -25,045.26 |
| Dec 31, 2022 | 55,093.36 |
| Dec 31, 2022 | 55,093.36 |
| Sep 22, 2022 | 56,345.74 |
| Sep 22, 2022 | 56,345.74 |
| Dec 31, 2021 | 93,805.62 |
| Dec 31, 2021 | 93,805.62 |
| Jun 30, 2021 | -2.64 Mn |
| Jun 30, 2021 | -2.64 Mn |
| Mar 31, 2021 | -2.71 Mn |
| Mar 31, 2021 | -2.71 Mn |